Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Mark R, Charbonneau"'
Autor:
David Lubkowicz, Nicholas G Horvath, Michael J James, Pasquale Cantarella, Lauren Renaud, Christopher G Bergeron, Ron B Shmueli, Cami Anderson, Jian‐Rong Gao, Caroline B Kurtz, Mylene Perreault, Mark R Charbonneau, Vincent M Isabella, David L Hava
Publikováno v:
Molecular Systems Biology, Vol 18, Iss 3, Pp 1-17 (2022)
Abstract Enteric hyperoxaluria (EH) is a metabolic disease caused by excessive absorption of dietary oxalate leading to the formation of chronic kidney stones and kidney failure. There are no approved pharmaceutical treatments for EH. SYNB8802 is an
Externí odkaz:
https://doaj.org/article/b6d895d2871d4ce49bd1ee066df28241
Autor:
Mark R. Charbonneau, William S. Denney, Nicholas G. Horvath, Pasquale Cantarella, Mary J. Castillo, Marja K. Puurunen, Aoife M. Brennan
Publikováno v:
Communications Biology, Vol 4, Iss 1, Pp 1-12 (2021)
Mark Charbonneau et al. develop a mathematical model that describes the behavior of an engineered bacterial therapeutic, SYNB1618, in the human gastrointestinal tract and its effects on plasma phenylalanine (Phe) levels. This model enables the author
Externí odkaz:
https://doaj.org/article/9c842b6d19dd4ea5ab162237138ababd
Autor:
M. Tyler Nelson, Mark R. Charbonneau, Heidi G. Coia, Mary J. Castillo, Corey Holt, Eric S. Greenwood, Peter J. Robinson, Elaine A. Merrill, David Lubkowicz, Camilla A. Mauzy
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-13 (2021)
Engineered live bacteria could represent a new class of therapeutic treatment for human disease. Here, the authors use a human gut-on-a-chip microfluidics system to characterize an engineered live bacterial therapeutic, designed for the treatment of
Externí odkaz:
https://doaj.org/article/229bd7533d5f4591b5fea3903111b0fd
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-11 (2020)
The role microbes play in human health and the ability of synthetic biology to engineer microbial properties opens up new ways of treating disease. In this perspective, the authors describe the design and development of these living therapeutics.
Externí odkaz:
https://doaj.org/article/26fba4ca08df4eda919a1a6132d74277
Autor:
Aoife M. Brennan, Larry Blankstein, Mark R. Charbonneau, Mary Castillo, John A. Phillips, Benjamin D. Goodlett, William S. Denney, Caroline B. Kurtz, David A. Wagner, Jerry Vockley, Marja K. Puurunen, Stephanie Sacharow, Vincent M. Isabella, Vasu V. Sethuraman, Richard Riese, Shawn Searle
Publikováno v:
Nature Metabolism. 3:1125-1132
Phenylketonuria (PKU) is a rare disease caused by biallelic mutations in the PAH gene that result in an inability to convert phenylalanine (Phe) to tyrosine, elevated blood Phe levels and severe neurological complications if untreated. Most patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1342478a5d170a500dcfa6ea1b086228
https://doi.org/10.1038/s42255-021-00430-7
https://doi.org/10.1038/s42255-021-00430-7
Autor:
Elaine A. Merrill, Peter J Robinson, Camilla A Mauzy, Heidi G. Coia, Corey Holt, Eric S. Greenwood, Mark R. Charbonneau, Mary Castillo, David Lubkowicz, M. Tyler Nelson
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-13 (2021)
Nature Communications
Nature Communications
Engineered bacteria (synthetic biotics) represent a new class of therapeutics that leverage the tools of synthetic biology. Translational testing strategies are required to predict synthetic biotic function in the human body. Gut-on-a-chip microfluid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48c4264fa5a0d61486826735ca39438e
https://doaj.org/article/229bd7533d5f4591b5fea3903111b0fd
https://doaj.org/article/229bd7533d5f4591b5fea3903111b0fd
Autor:
Aoife M. Brennan, Nicholas G. Horvath, William S. Denney, Mary Castillo, Pasquale Cantarella, Mark R. Charbonneau, Marja K. Puurunen
Publikováno v:
Communications Biology
Communications Biology, Vol 4, Iss 1, Pp 1-12 (2021)
Communications Biology, Vol 4, Iss 1, Pp 1-12 (2021)
The development of therapeutics depends on predictions of clinical activity from pre-clinical data. We have previously described SYNB1618, an engineered bacterial therapeutic (synthetic biotic) for the treatment of Phenylketonuria (PKU), a rare genet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d96870b0f2136283ec18a8b4d6c36f2
https://doi.org/10.1038/s42003-021-02183-1
https://doi.org/10.1038/s42003-021-02183-1
Autor:
Marja K. Puurunen, Jerry Vockley, Shawn L. Searle, Stephanie J. Sacharow, John A. Phillips, William S. Denney, Benjamin D. Goodlett, David A. Wagner, Larry Blankstein, Mary J. Castillo, Mark R. Charbonneau, Vincent M. Isabella, Vasu V. Sethuraman, Richard J. Riese, Caroline B. Kurtz, Aoife M. Brennan
Publikováno v:
Nature Metabolism. 4:1214-1214
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::05de650ff6c47d4b608240b7940f8363
https://doi.org/10.1038/s42255-022-00635-4
https://doi.org/10.1038/s42255-022-00635-4
Autor:
Marja K, Puurunen, Jerry, Vockley, Shawn L, Searle, Stephanie J, Sacharow, John A, Phillips, William S, Denney, Benjamin D, Goodlett, David A, Wagner, Larry, Blankstein, Mary J, Castillo, Mark R, Charbonneau, Vincent M, Isabella, Vasu V, Sethuraman, Richard J, Riese, Caroline B, Kurtz, Aoife M, Brennan
Publikováno v:
Nature metabolism. 3(8)
Phenylketonuria (PKU) is a rare disease caused by biallelic mutations in the PAH gene that result in an inability to convert phenylalanine (Phe) to tyrosine, elevated blood Phe levels and severe neurological complications if untreated. Most patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f82627a32b8de2935eacdf630d65bebf
https://pubmed.ncbi.nlm.nih.gov/35974248
https://pubmed.ncbi.nlm.nih.gov/35974248
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-11 (2020)
Nature Communications
Nature Communications
A complex interplay of metabolic and immunological mechanisms underlies many diseases that represent a substantial unmet medical need. There is an increasing appreciation of the role microbes play in human health and disease, and evidence is accumula
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::284b69a13a6b37410a562bc6161cca97
https://doi.org/10.1038/s41467-020-15508-1
https://doi.org/10.1038/s41467-020-15508-1